Tovecimig (CTX-009)

Second-line advanced biliary tract cancer is a setting with no FDA-approved systemic therapy for the approximately 85% of participants whose tumours carry no actionable alteration. The standard of care rests on a single positive phase 3 trial, ABC-06, in which FOLFOX extended median overall survival from 5.3 to 6.2 months and produced an objective response in 4 of 81 participants (5%), and the Pan-Asian adaptation of the ESMO guideline has downgraded that recommendation from level of evidence I to II and grade A to B.

Against that background, COMPANION-002 met its primary endpoint. Tovecimig plus paclitaxel roughly tripled the objective response rate relative to paclitaxel alone (18.0% versus 5.3%, p=0.0228, all responses confirmed by blinded independent central review) and nearly doubled median progression-free survival (4.7 versus 2.6 months, hazard ratio 0.44, p<0.0001). These are the largest randomized response and progression-free survival differences reported in this setting.

The trial did not demonstrate an overall survival benefit. Median overall survival was 8.9 months with tovecimig plus paclitaxel versus 9.4 months in the control arm (hazard ratio 1.05, p=0.78), and the prespecified crossover adjustment did not change that result (hazard ratio 1.13, p=0.65). Crossover of 31 of 57 control participants (54%) means 142 of 168 participants (85%) received tovecimig, which limits what the survival comparison can show, but the analyses the sponsor offers in support of a survival effect are post hoc comparisons of non-randomized subgroups, and one of them shows the crossover and non-crossover subgroups differed in progression rate on paclitaxel alone before crossover occurred.

For a pharmacy and therapeutics committee, four considerations follow. First, the efficacy claim rests on response rate and progression-free survival, not survival, in a population whose median survival is under one year. Second, all pivotal results are sponsor documents filed with the U.S. Securities and Exchange Commission and are not peer reviewed; duration of response, disposition, deaths, serious adverse events, discontinuations, disease control rate, and the prespecified quality-of-life endpoint are unreported, and the complete dataset was scheduled for presentation in October 2026. Third, the added toxicity is measurable and manageable but not trivial, with grade 3 or higher hypertension in 52% of the tovecimig arm against 6% of the control arm. Fourth, no price has been announced, no economic model exists, and because the comparator is generic paclitaxel the whole incremental cost of the regimen will be the price of tovecimig; the sponsor guides to a Biologics License Application in the fourth quarter of 2026 and potential approval and launch in 2027, so a placement decision is likely to be required before peer-reviewed evidence is available.